Pharvaris Prices Underwritten Offering of 3,874,664 Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PHVS?
Source: Newsfilter
- Offering Size: Pharvaris announced the pricing of 3,874,664 ordinary shares at $29.68 each, expecting to raise approximately $115 million, reflecting the company's strong financing capability and market confidence in the biopharmaceutical sector.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the offering, indicating robust support and professional partnerships in the capital markets.
- Additional Share Option: Pharvaris granted underwriters a 30-day option to purchase up to 581,199 additional shares, enhancing the flexibility of the financing and potential inflow of funds.
- Clinical Trial Progress: Ongoing Phase 3 trials, CHAPTER-3 and CREAATE, for the new drug deucrictibant are expected to provide critical data for market prospects, with topline results anticipated in Q3 2026, potentially boosting future market acceptance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHVS
Wall Street analysts forecast PHVS stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 29.680
Low
30.00
Averages
41.00
High
60.00
Current: 29.680
Low
30.00
Averages
41.00
High
60.00
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharvaris Prices Underwritten Offering of 3.87 Million Shares
- Offering Size: Pharvaris has priced an underwritten offering of 3.87 million ordinary shares at $29.68 per share, with gross proceeds expected to be approximately $115 million, which will provide crucial funding for the company's research and operations.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 581,199 ordinary shares, which may further enhance the company's capital structure and market liquidity.
- Market Reaction: Following the announcement of the offering, Pharvaris's stock traded 1.5% higher during pre-market hours on Friday, indicating a positive market response to the company's financing activities and potentially boosting investor confidence.
- Future Outlook: The offering is expected to close on or about May 11, 2026, with the funds aimed at supporting the company's further development and innovation in the global angioedema space, thereby enhancing its competitive position in the market.
See More
Pharvaris Prices Underwritten Offering of 3,874,664 Shares
- Offering Size: Pharvaris announced the pricing of 3,874,664 ordinary shares at $29.68 each, expecting to raise approximately $115 million, reflecting the company's strong financing capability and market confidence in the biopharmaceutical sector.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the offering, indicating robust support and professional partnerships in the capital markets.
- Additional Share Option: Pharvaris granted underwriters a 30-day option to purchase up to 581,199 additional shares, enhancing the flexibility of the financing and potential inflow of funds.
- Clinical Trial Progress: Ongoing Phase 3 trials, CHAPTER-3 and CREAATE, for the new drug deucrictibant are expected to provide critical data for market prospects, with topline results anticipated in Q3 2026, potentially boosting future market acceptance.
See More
Pharvaris Director Sells 7,100 Shares Under Rule 10b5-1 Plan
- Transaction Overview: Director Johannes Schikan sold 7,100 shares of Pharvaris N.V. between April 22 and 23 through open-market transactions, totaling approximately $213,000, leaving him with 388,067 shares valued at about $10.59 million post-transaction.
- Change in Holdings: The sale of 7,100 shares represents 1.80% of Schikan's direct holdings, indicating a modest reduction while still retaining nearly 400,000 shares, which reflects ongoing confidence in the company's future prospects.
- Transaction Context: This transaction was executed under a pre-scheduled Rule 10b5-1 trading plan, signaling planned liquidity management rather than a shift in Schikan's outlook, with no indirect holdings or derivative securities involved.
- Future Development Outlook: Pharvaris anticipates topline data from its pivotal CHAPTER-3 study in Q3 2026 and plans to submit a U.S. NDA for on-demand hereditary angioedema treatment in the first half of 2026, indicating that key regulatory milestones will significantly impact the stock more than insider sales.
See More
Schikan Sells Shares of Pharvaris N.V.
- Share Sale Details: Schikan sold 7,100 shares of Pharvaris N.V. over two transactions on April 22 and 23 for approximately $213,000, using a weighted average sale price of $30.05 per share, reducing his direct holdings by 1.80%.
- Holding Changes: Following this transaction, Schikan's direct stake decreased from 395,167 shares to 388,067 shares, retaining a direct position valued at about $10.59 million, indicating his continued confidence in the company's future prospects.
- Company Overview: Pharvaris N.V. is a clinical-stage biopharmaceutical firm specializing in innovative oral therapies for rare diseases, particularly hereditary angioedema, aiming to address significant unmet medical needs in this niche market.
- Future Outlook: The company expects to release topline data from its pivotal Phase 3 study of deucrictibant XR for prophylactic hereditary angioedema treatment in Q3 2026 and plans to submit a U.S. NDA for deucrictibant IR for on-demand HAE treatment in the first half of 2026, with these regulatory milestones likely to have a more significant impact on stock performance than insider sales.
See More
Pharvaris CEO Sells 23,333 Shares Amid Strong Stock Performance
- Insider Sale: On April 9, 2026, Pharvaris CEO Berndt Modig sold 23,333 common shares for approximately $647,000, reducing his direct holdings to 142,084 shares, indicating routine liquidity management under his trading plan.
- Stake Analysis: This sale represented 14.11% of Modig's direct stake but only 2.09% of his total holdings, suggesting confidence in the company as he retains over 900,000 shares indirectly.
- Market Price Comparison: The weighted average sale price of $27.74 per share was slightly above the latest closing price of $26.63 on April 10, 2026, indicating a strategic decision to sell at a high point amidst market fluctuations.
- Investor Considerations: Despite Pharvaris not generating revenue and reporting a net loss of €176 million in 2025, its cash reserves increased to €292 million, providing operational funding, while investors should monitor the approval status of its treatment options before making investment decisions.
See More
Pharvaris Reports Q4 Loss of €46.7 Million
- Financial Performance: Pharvaris reported a Q4 loss of €46.7 million, resulting in a basic and diluted loss per share of €0.72, indicating significant pressure from R&D and operational expenditures that may affect future financing capabilities.
- Market Reaction: The ongoing losses may undermine investor confidence in Pharvaris, leading to increased stock price volatility and impacting the company's positioning in the biopharmaceutical sector.
- Conference Presentations: Pharvaris showcased its developments at the 2026 Global Angioedema Leadership Conference and the AAAAI Annual Meeting, aiming to enhance brand visibility and attract potential investors despite its poor financial performance.
- Historical Financial Data: The disclosure of historical financial data reveals a trend of sustained losses over recent quarters, potentially raising market concerns about the company's long-term sustainability.
See More
Pharvaris Prices Underwritten Offering of 3.87 Million Shares
- Offering Size: Pharvaris has priced an underwritten offering of 3.87 million ordinary shares at $29.68 per share, with gross proceeds expected to be approximately $115 million, which will provide crucial funding for the company's research and operations.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 581,199 ordinary shares, which may further enhance the company's capital structure and market liquidity.
- Market Reaction: Following the announcement of the offering, Pharvaris's stock traded 1.5% higher during pre-market hours on Friday, indicating a positive market response to the company's financing activities and potentially boosting investor confidence.
- Future Outlook: The offering is expected to close on or about May 11, 2026, with the funds aimed at supporting the company's further development and innovation in the global angioedema space, thereby enhancing its competitive position in the market.
See More
Pharvaris Prices Underwritten Offering of 3,874,664 Shares
- Offering Size: Pharvaris announced the pricing of 3,874,664 ordinary shares at $29.68 each, expecting to raise approximately $115 million, reflecting the company's strong financing capability and market confidence in the biopharmaceutical sector.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the offering, indicating robust support and professional partnerships in the capital markets.
- Additional Share Option: Pharvaris granted underwriters a 30-day option to purchase up to 581,199 additional shares, enhancing the flexibility of the financing and potential inflow of funds.
- Clinical Trial Progress: Ongoing Phase 3 trials, CHAPTER-3 and CREAATE, for the new drug deucrictibant are expected to provide critical data for market prospects, with topline results anticipated in Q3 2026, potentially boosting future market acceptance.
See More
Pharvaris Director Sells 7,100 Shares Under Rule 10b5-1 Plan
- Transaction Overview: Director Johannes Schikan sold 7,100 shares of Pharvaris N.V. between April 22 and 23 through open-market transactions, totaling approximately $213,000, leaving him with 388,067 shares valued at about $10.59 million post-transaction.
- Change in Holdings: The sale of 7,100 shares represents 1.80% of Schikan's direct holdings, indicating a modest reduction while still retaining nearly 400,000 shares, which reflects ongoing confidence in the company's future prospects.
- Transaction Context: This transaction was executed under a pre-scheduled Rule 10b5-1 trading plan, signaling planned liquidity management rather than a shift in Schikan's outlook, with no indirect holdings or derivative securities involved.
- Future Development Outlook: Pharvaris anticipates topline data from its pivotal CHAPTER-3 study in Q3 2026 and plans to submit a U.S. NDA for on-demand hereditary angioedema treatment in the first half of 2026, indicating that key regulatory milestones will significantly impact the stock more than insider sales.
See More
Schikan Sells Shares of Pharvaris N.V.
- Share Sale Details: Schikan sold 7,100 shares of Pharvaris N.V. over two transactions on April 22 and 23 for approximately $213,000, using a weighted average sale price of $30.05 per share, reducing his direct holdings by 1.80%.
- Holding Changes: Following this transaction, Schikan's direct stake decreased from 395,167 shares to 388,067 shares, retaining a direct position valued at about $10.59 million, indicating his continued confidence in the company's future prospects.
- Company Overview: Pharvaris N.V. is a clinical-stage biopharmaceutical firm specializing in innovative oral therapies for rare diseases, particularly hereditary angioedema, aiming to address significant unmet medical needs in this niche market.
- Future Outlook: The company expects to release topline data from its pivotal Phase 3 study of deucrictibant XR for prophylactic hereditary angioedema treatment in Q3 2026 and plans to submit a U.S. NDA for deucrictibant IR for on-demand HAE treatment in the first half of 2026, with these regulatory milestones likely to have a more significant impact on stock performance than insider sales.
See More
Pharvaris CEO Sells 23,333 Shares Amid Strong Stock Performance
- Insider Sale: On April 9, 2026, Pharvaris CEO Berndt Modig sold 23,333 common shares for approximately $647,000, reducing his direct holdings to 142,084 shares, indicating routine liquidity management under his trading plan.
- Stake Analysis: This sale represented 14.11% of Modig's direct stake but only 2.09% of his total holdings, suggesting confidence in the company as he retains over 900,000 shares indirectly.
- Market Price Comparison: The weighted average sale price of $27.74 per share was slightly above the latest closing price of $26.63 on April 10, 2026, indicating a strategic decision to sell at a high point amidst market fluctuations.
- Investor Considerations: Despite Pharvaris not generating revenue and reporting a net loss of €176 million in 2025, its cash reserves increased to €292 million, providing operational funding, while investors should monitor the approval status of its treatment options before making investment decisions.
See More
Pharvaris Reports Q4 Loss of €46.7 Million
- Financial Performance: Pharvaris reported a Q4 loss of €46.7 million, resulting in a basic and diluted loss per share of €0.72, indicating significant pressure from R&D and operational expenditures that may affect future financing capabilities.
- Market Reaction: The ongoing losses may undermine investor confidence in Pharvaris, leading to increased stock price volatility and impacting the company's positioning in the biopharmaceutical sector.
- Conference Presentations: Pharvaris showcased its developments at the 2026 Global Angioedema Leadership Conference and the AAAAI Annual Meeting, aiming to enhance brand visibility and attract potential investors despite its poor financial performance.
- Historical Financial Data: The disclosure of historical financial data reveals a trend of sustained losses over recent quarters, potentially raising market concerns about the company's long-term sustainability.
See More
